Industry Seeks Changes In FDA Drug/Diagnostic Co-Development Model
FDA should employ more realistic timelines for drug/diagnostic co-development when it crafts draft guidance on the topic, stakeholders argue in written comments to the agency
FDA should employ more realistic timelines for drug/diagnostic co-development when it crafts draft guidance on the topic, stakeholders argue in written comments to the agency